西妥昔单抗联合放化疗治疗中晚期鼻咽癌的临床观察

目的　观察调强放疗（ＩＭＲＴ）联合西妥昔单抗（Ｃｅｔｕｘｉｍａｂ，Ｃ２２５）治疗鼻咽癌患者的近期疗效和毒副反应。方法　回顾性分析１０例中晚期鼻咽癌患者调强放疗联合Ｃ２２５治疗的临床资料，患者行鼻咽部病灶及颈淋巴结引流区的调强放疗，放疗同步加用Ｃ２２５每周１次静脉滴注，首剂４００ｍｇ／ｍ^２，以后每周２５０ｍｇ／ｍ^２，共８周。结果　１０例患者全部完成治疗，均评价为ＣＲ，有效率为１００％。主要毒副反应为痤疮样皮疹及口腔黏膜反应。结论　放化疗同步加用Ｃ２２５治疗鼻咽癌近期疗效好，其毒副反应患者尚可耐受，其远期疗效有待进一步观察。

The clinical observation of intensity modulated radiation therapy combined with cetuximab for nasopharyngeal carcinoma

Objective To observate the therapeutic effects and toxicity of intensity modulated radiation therapy(IMRT) combined with cetuximab(C225) in advanced nasopharyngeal carcinoma.Methods Ten patients with nasopharyngeal carcinoma(NPC) treated with IMRT combined with C225 that was given intravenously with an initial dose of 400mg/m2 in the first week followed by weekly injection of 250mg/m2 for 8 weeks.Results All 10 patients completed the planned treatment,which all achieved completely remission.The immediate re...